Microglial cells: the main HIV-1 reservoir in the brain
C Wallet, M De Rovere, J Van Assche… - Frontiers in cellular …, 2019 - frontiersin.org
Despite efficient combination of the antiretroviral therapy (cART), which significantly
decreased mortality and morbidity of HIV-1 infection, a definitive HIV cure has not been …
decreased mortality and morbidity of HIV-1 infection, a definitive HIV cure has not been …
The latent reservoir of inducible, infectious HIV-1 does not decrease despite decades of antiretroviral therapy
NF McMyn, J Varriale, EJ Fray… - The Journal of …, 2023 - Am Soc Clin Investig
HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …
[HTML][HTML] HIV-1 remission and possible cure in a woman after haplo-cord blood transplant
Previously, two men were cured of HIV-1 through CCR5Δ32 homozygous (CCR5Δ32/Δ32)
allogeneic adult stem cell transplant. We report the first remission and possible HIV-1 cure in …
allogeneic adult stem cell transplant. We report the first remission and possible HIV-1 cure in …
Targeting the latent reservoir for HIV-1
S Sengupta, RF Siliciano - Immunity, 2018 - cell.com
Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …
Identification of genetically intact HIV-1 proviruses in specific CD4+ T cells from effectively treated participants
Latent replication-competent HIV-1 persists in individuals on long-term antiretroviral therapy
(ART). We developed the Full-Length Individual Proviral Sequencing (FLIPS) assay to …
(ART). We developed the Full-Length Individual Proviral Sequencing (FLIPS) assay to …
Effect of HIV antibody VRC01 on viral rebound after treatment interruption
KJ Bar, MC Sneller, LJ Harrison… - … England Journal of …, 2016 - Mass Medical Soc
Background The discovery of potent and broadly neutralizing antibodies (bNAbs) against
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …
human immunodeficiency virus (HIV) has made passive immunization a potential strategy …
CD4+ T Cells Expressing PD-1, TIGIT and LAG-3 Contribute to HIV Persistence during ART
R Fromentin, W Bakeman, MB Lawani, G Khoury… - PLoS …, 2016 - journals.plos.org
HIV persists in a small pool of latently infected cells despite antiretroviral therapy (ART).
Identifying cellular markers expressed at the surface of these cells may lead to novel …
Identifying cellular markers expressed at the surface of these cells may lead to novel …
[HTML][HTML] Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure
Antiretroviral therapy fails to cure HIV-1 infection because latent proviruses persist in resting
CD4+ T cells. T cell activation reverses latency, but< 1% of proviruses are induced to …
CD4+ T cells. T cell activation reverses latency, but< 1% of proviruses are induced to …
Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group …
TA Rasmussen, M Tolstrup, CR Brinkmann… - The lancet HIV, 2014 - thelancet.com
Background Activating the expression of latent virus is an approach that might form part of
an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to …
an HIV cure. We assessed the ability of the histone deacetylase inhibitor panobinostat to …